MedTrace Logo

Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus

NCT02426541 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2018-02-05

Study results available
· View outcomes & findings →

Summary

This is an 8-week, single centre, randomized, parallel-group, double-blind, placebo-controlled Phase IV study to evaluate the effect of dapagliflozin on tissue specific insulin sensitivity in patients with Type 2 diabetes mellitus

Conditions

Interventions

DRUG

Dapagliflozin

Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks

DRUG

Placebo

Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks

Sponsors & Collaborators

  • Antaros Medical

    collaborator INDUSTRY

  • Bioventure Hub

    collaborator UNKNOWN

  • 43183 Mölndal

    collaborator UNKNOWN

  • Sweden

    collaborator UNKNOWN

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Pirjo Nuutila, MD, PhD, Professor · Turku PET Centre, Turku, Finland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-23
Primary Completion
2016-04-28
Completion
2016-04-28

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02426541 on ClinicalTrials.gov